Structure Therapeutics Q1 net loss $46.8M; cash $836.9M; aleniglipron Ph2b data expected by year-end

Structure Therapeutics Inc.

2025-Q1 EPS reported -$0.27

Net loss of $46.8M in Q1 2025 vs $26.0M in Q1 2024; R&D expenses $42.9M (up from $20.7M).
Cash, equivalents and short-term investments $836.9M as of March 31, 2025; funding through at least 2027.
Phase 2b ACCESS and ACCESS II fully enrolled; topline 36-week data for aleniglipron expected by year-end 2025.
Initiation of Phase 1 study for oral amylin agonist ACCG-2671 planned by year-end 2025; new preclinical data at ADA June 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.